View of Immune-mediated cutaneous adverse effects as markers of good therapeutic response to checkpoint inhibitors, especially in melanoma

Return to Issue Details Immune-mediated cutaneous adverse effects as markers of good therapeutic response to checkpoint inhibitors, especially in melanoma Download Download PDF